mk 677 vs tesamorelin: Frequently asked questions

Tesamorelin + Ipamorelin preserves glucose metabolism significantly better than MK-677. The pulsatile mechanism prevents chronic IGF-1 elevation that impairs peripheral insulin signaling. 16-week studies show no meaningful change in HbA1c or HOMA-IR on the blend, compared to 8–12 mg/dL fasting glucose increases with MK-677. If insulin resistance is a confounding variable in your model, the blend is the safer choice for protocols exceeding 12 weeks without cycling.

Choose MK-677. It's the only orally active growth hormone secretagogue with established clinical efficacy. Take 12.5–25 mg once daily at bedtime to minimize daytime hunger effects. Accept that appetite stimulation and mild insulin resistance are part of the package. These are ghrelin-mediated effects you cannot separate from the GH-boosting mechanism. Monitor fasting glucose every 4–6 weeks; if it climbs above 100 mg/dL, reduce dose or discontinue.

Tesamorelin is the only GH-related compound with FDA approval and Phase 3 trial data specifically for visceral adipose tissue reduction. The TRIM study showed 15% VAT reduction after 26 weeks at 2 mg daily. MK-677 has no comparable evidence. Tesamorelin works by restoring GH pulsatility, which preferentially mobilizes visceral fat through lipolytic signaling in abdominal adipocytes. If subcutaneous injection is acceptable and abdominal fat is the measurable endpoint, tesamorelin is the evidence-based choice.

The Tesamorelin + Ipamorelin blend outperforms MK-677 for acute fat metabolism studies. Pulsatile GH spikes activate hormone-sensitive lipase more effectively than continuous low-level elevation, producing measurably higher free fatty acid release from subcutaneous and visceral adipose depots. Dose the blend once daily at bedtime to align peak GH secretion with natural nocturnal lipolytic activity. This timing maximizes fat oxidation while preserving daytime insulin sensitivity.

Choose MK-677. Oral administration eliminates the logistical burden of reconstitution, cold storage, and daily injections. Critical for extended studies where compliance and storage infrastructure matter. Expect steady IGF-1 elevation within three weeks, but implement 4-week washouts every 8–12 weeks to mitigate receptor desensitization. Monitor fasting glucose monthly if using doses above 15mg daily, as insulin resistance risk increases with chronic use beyond 12 weeks.

Water retention (peripheral edema, joint stiffness) occurs in 20–30% of MK-677 users, especially at doses above 20 mg daily. This is a direct consequence of elevated GH and aldosterone signaling. Not a contamination issue. Reduce dose to 12.5 mg and assess tolerance over two weeks. If edema persists, discontinue MK-677 and consider tesamorelin instead, which causes significantly less fluid retention because it restores pulsatile GH rather than creating sustained elevation.

Avoid MK-677. Ghrelin receptor agonism impairs insulin sensitivity in a dose-dependent manner, and fasting glucose typically rises 10–15 mg/dL after six months at 25 mg daily. Tesamorelin does not share this liability because GHRH signaling does not activate orexigenic pathways or interfere with glucose metabolism. If GH elevation is necessary and insulin sensitivity matters, tesamorelin is the safer option. Monitor HbA1c and fasting glucose regardless. Any compound that raises IGF-1 has downstream metabolic effects worth tracking.